These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 24909984

  • 1. Weight-neutral effect of once-daily insulin detemir in Chinese type 2 diabetes patients: subgroup analysis of the SOLVE study.
    Pan C, Han P, Ji L, Ji Q, Lu J, Lin J, Liu J, Su B, Shi J, Wang P.
    J Diabetes; 2015 Mar; 7(2):222-30. PubMed ID: 24909984
    [Abstract] [Full Text] [Related]

  • 2. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Sreenan S, Kozlovski P, Hansen JB, Looij BJ, Meneghini L, PREDICTIVE Study Group.
    Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
    [Abstract] [Full Text] [Related]

  • 3. Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
    Caputo S, Maran A, Mannino D, Morano S, Lastoria G, Nicoziani P.
    Minerva Endocrinol; 2015 Dec; 40(4):249-58. PubMed ID: 26551483
    [Abstract] [Full Text] [Related]

  • 4. [The safety and effectiveness of once daily detemir in patients with type 2 diabetes previously failing oral agents: the Chinese cohort from SOLVE(TM) observational study].
    Pan CY, Ji LN, Lu JM, Yang WY, Zhou ZG, Zou DJ, Ji QH, Han P, Liu J, Li Q, Su BL, Li YB, Gao ZN, Wang PH, Yin SN, Dong YH, Yang T, Sun K, Li H, Hong X, Lin J, Shi JM, Yang XJ, Fang H, Yan XD, SOLVE™ Chinese study group.
    Zhonghua Nei Ke Za Zhi; 2013 Jan; 52(1):11-5. PubMed ID: 23710808
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
    Dornhorst A, Lüddeke HJ, Sreenan S, Koenen C, Hansen JB, Tsur A, Landstedt-Hallin L.
    Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
    [Abstract] [Full Text] [Related]

  • 6. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J, Caputo S, Damci T, Orozco-Beltran D, Pan C, Svendsen AL, Sølje KS, Khunti K, SOLVE study group.
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [Abstract] [Full Text] [Related]

  • 7. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

  • 8. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF, Dornhorst A, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
    [Abstract] [Full Text] [Related]

  • 9. [Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)].
    Liebl A, Wilhelm B, Kaiser M.
    MMW Fortschr Med; 2012 Dec 17; 154 Suppl 4():102-9. PubMed ID: 23326928
    [Abstract] [Full Text] [Related]

  • 10. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L, Koenen C, Weng W, Selam JL.
    Diabetes Obes Metab; 2007 Nov 17; 9(6):902-13. PubMed ID: 17924873
    [Abstract] [Full Text] [Related]

  • 11. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice.
    Ross S, Dzida G, Ji Q, Kaiser M, Ligthelm R, Meneghini L, Nazeri A, Orozco-Beltran D, Pan C, Svendsen AL, SOLVE Study Group.
    J Diabetes; 2014 May 17; 6(3):243-50. PubMed ID: 24103141
    [Abstract] [Full Text] [Related]

  • 12. Improved glycaemic control with no weight gain: a 26-week, open label, non-randomised, non-interventional observational study on type 2 diabetes subjects using insulin detemir.
    Tripathi S, Chandalia HB, Rao PV, Badgandi M, Patni R, Subbanna PK, Shetty R, Kumar H.
    J Indian Med Assoc; 2011 Apr 17; 109(4):275-8. PubMed ID: 22187803
    [Abstract] [Full Text] [Related]

  • 13. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G.
    Rom J Intern Med; 2003 Apr 17; 41(2):153-62. PubMed ID: 15526500
    [Abstract] [Full Text] [Related]

  • 14. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.
    Marre M, Pinget M, Gin H, Thivolet C, Hanaire H, Robert JJ, Fontaine P.
    Diabetes Metab; 2009 Dec 17; 35(6):469-75. PubMed ID: 19914118
    [Abstract] [Full Text] [Related]

  • 15. [RESOLUTE Study in the Czech Republic: insulin glargine improves the compensation of type 2 diabetes in patients with unsatisfactory results of therapy with a combination of insulin detemir and oral antidiabetics. Results of the nonintervention RESOLUTE Project in the Czech Republic].
    Kvapil M.
    Vnitr Lek; 2013 Sep 17; 59(9):800-6. PubMed ID: 24073952
    [Abstract] [Full Text] [Related]

  • 16. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y, Guo XH, Vaz JA, PRESENT Study Group.
    Diabetes Obes Metab; 2009 Jan 17; 11(1):33-40. PubMed ID: 18494806
    [Abstract] [Full Text] [Related]

  • 17. Are insulin analogues detemir or glulisine used preferentially in overweight/obese subjects? A German multicentre analysis of 38560 type 2 diabetic patients from the DPV registry.
    Bohn B, Scheuing N, Jehle PM, Laubner K, Born B, Merger S, Hummel M, Krakow D, Voll A, Zimmermann A, Zimny S, Holl RW, DPV and APV initiatives and the German BMBF Competence Networks Diabetes mellitus and Obesity.
    Exp Clin Endocrinol Diabetes; 2014 Nov 17; 122(10):602-7. PubMed ID: 25054308
    [Abstract] [Full Text] [Related]

  • 18. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.
    Diabetes Obes Metab; 2005 Jan 17; 7(1):56-64. PubMed ID: 15642076
    [Abstract] [Full Text] [Related]

  • 19. Weight change upon once-daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin-naïve individuals with type 2 diabetes: results from the DIET trial.
    Niswender K, Piletic M, Andersen H, Conradsen Hiort L, Hollander P.
    Diabetes Obes Metab; 2014 Feb 17; 16(2):186-92. PubMed ID: 24112375
    [Abstract] [Full Text] [Related]

  • 20. Improved glycemic control with weight loss and a low risk of hypoglycemia with insulin detemir: insights from the Italian cohort of the PREDICTIVE study after 6-month observation in type 2 diabetic subjects.
    Perriello G, Caputo S, De Pergola G, Di Carlo A, Grassi G, Lapolla A, Pata P, Solerte SB, Zaccardi F.
    Expert Opin Pharmacother; 2011 Nov 17; 12(16):2449-55. PubMed ID: 21988213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.